彩色多普勒超声检测子宫内膜和内膜下血流评价IVF-ET结局

目的:探讨hCG注射日应用彩色多普勒超声检测子宫内膜和内膜下血流预测IVF-ET的结局。方法:应用彩色多普勒超声检测hCG注射日子宫内膜和内膜下血流分布情况,将115例IVF-ET/ICSI-ET助孕患者分为A组(n=56):子宫内膜和内膜下均有血流通过;B组(n=42):内膜下有血流但内膜没有血流通过;C组(n=17):内膜和内膜下均无血流通过。随访IVF-ET结局,按妊娠与否分为妊娠组(n=53)与非妊娠组(n=62)。比较A、B、C组的临床特征、卵巢反应、内膜厚度及类型和妊娠结局;比较妊娠组与非妊娠组内膜厚度和类型。结果:A、B、C组间的临床特征、卵巢反应差异无统计学意义,内膜厚度C组低于A组和B组(P<0.05),但3组内膜形态比较差异无统计学意义;A、B、C组妊娠率(62.5%、33.3%、23.5%)和种植率(37.9%、18.4%、10.8%)比较差异有统计学意义(P<0.05)。妊娠组与非妊娠组的内膜厚度及类型比较差异均无统计学意义。结论:hCG注射日应用彩色多普勒超声检测子宫内膜和内膜下血流对IVF-ET的结局有一定的预测价值,是一种较好的、能在临床上普遍开展的无创伤性的预测方法。     

促排卵过程中子宫内膜厚度变化对IVF-ET结局的影响

目的:探讨促排卵过程中子宫内膜厚度变化趋势对IVF结局的影响,以及不同促排卵方案对子宫内膜厚度变化趋势的影响。方法:回顾性分析1 173个IVF-ET周期,控制性促排卵方案包括:长方案(568例)、口服避孕药(OC)+GnRHa方案(425例)、拮抗剂方案(107例)和超长方案(73例)。比较各种促排卵方案的妊娠组与非妊娠组的子宫内膜厚度变化情况,包括Gn启动当日、启动后第5日、hCG注射日及子宫内膜差值1(=启动后第5日内膜厚度-启动当日内膜厚度)、子宫内膜差值2(=hCG注射日内膜厚度-启动后第5日内膜厚度)、子宫内膜差值3(=hCG注射日内膜厚度-启动当日内膜厚度)。结果:hCG注射日子宫内膜厚度妊娠组均较未妊娠组显著增加(P<0.05);Gn启动当日子宫内膜厚度、促排卵第5日子宫内膜厚度、子宫内膜厚度差值1、差值2、差值3妊娠组与未妊娠组间均无统计学差异(P>0.05)。结论:促排卵过程中子宫内膜厚度的变化趋势不能预测IVF结果,不同的促排卵方案不影响子宫内膜厚度的变化趋势。     

滋阴补阳序贯法联合西药促排卵对PCOS患者的临床疗效分析

目的:探讨滋阴补阳序贯法联合西药促排卵对PCOS患者的临床疗效。方法:回顾性分析72例多囊卵巢综合征(PCOS)患者122个促排卵周期患者的临床资料,所有患者均于促排卵前后使用滋阴补阳中药进行序贯治疗。根据促排卵方案不同分为4组,A组:克罗米芬(CC)+促性腺激素(Gn)(n=71),B组:来曲唑(LE)+Gn(n=30),C组:CC(n=14),D组:Gn(n=7),比较各组间临床和实验室指标。结果:4组妊娠率比较:C组A组B组D组;Gn用量比较:D组B组A组,hCG注射日子宫内膜厚度:A组D组B组C组,但各指标组间比较均无统计学差异(P0.05),促排天数A组显著高于其它3组(P0.05)。hCG注射日子宫内膜厚度7 mm的比例CC组显著高于其它3组(P0.05)。4组未破裂卵泡黄素化综合征(LUFS)发生率、未启动率均无统计学差异(P0.05),无OHSS发生。按妊娠结局分组比较:bE2及bLH水平妊娠组未孕组,差异有统计学意义(P0.05)。妊娠组子宫内膜厚度显著高于未孕组,各组中A型内膜比例显著高于其它类型内膜。结论:对PCOS患者选择滋阴补阳序贯法联合CC+Gn促排卵能减少Gn用量,降低卵巢过度刺激综合征(OHSS)发生率,增加子宫内膜厚度,改善子宫内膜容受性,提高妊娠率。     

IVF/ICSI-ET周期hCG注射次日雌二醇(E_2)水平变化的意义

目的:探讨体外受精/卵胞质内单精子注射-胚胎移植(IVF/ICSI-ET)周期中hCG注射次日血清雌二醇(E2)水平较hCG注射日的增幅对超促排卵临床结局的预测价值。方法:回顾性分析362例行黄体中期长方案IVF/ICSI-ET患者的临床资料。hCG注射次日E2增幅=(hCG注射次日血清E2水平-hCG注射日E2水平)/hCG注射日E2水平×100%。根据增幅的不同分成4组:A组增幅20%,B组增幅为0.1%~20%间,C组为-20%~0%间,D组增幅-20%。分析4组患者基本临床资料、超促排卵情况以及临床结局各项指标。结果:各组患者的取卵年龄、不孕年限、基础FSH(bFSH)值、降调节剂量、rFSH天数、hCG用量、hCG注射日LH值、2原核(2PN)胚胎数、优质胚胎数、冷冻胚胎数各组间差异均无统计学意义。各组患者的Gn启动剂量、Gn总用量、hCG注射日P值差异均有统计学意义(P0.05),且各值随着E2增幅的降低逐渐升高。A组的临床妊娠率(56.30%)显著高于B、C、D组(40.27%、42.85%和20.00%),差异有统计学意义(P0.05)。A组的胚胎种植率(33.86%)虽高于B、C、D组(26.23%、28.65%和16.67%),但差异无统计学意义(P0.05)。结论:监测黄体中期长方案垂体降调节IVF/ICSI-ET患者hCG注射次日E2增幅水平对临床结局有预测意义,E2水平在hCG注射次日较hCG注射日增幅高达20%以上时,临床结局较好。     

温肾活血汤联合克罗米芬改善促排卵子宫内膜容受性疗效研究

目的:探讨温肾活血汤联合克罗米芬(clomiphene citrate,CC)促排卵治疗后对子宫内膜容受性的影响。方法:45例排卵障碍型不孕患者随机分成A组(CC)、B组(CC+阿司匹林)、C组(CC+温肾活血中药),每组15例。治疗1～3个疗程,观察排卵率、妊娠率及hCG注射日子宫内膜类型及厚度。结果:C组A+B型内膜率(91.18%)显著高于A组(76.92%,P<0.01)及B组(66.67%,P<0.05);C组内膜平均厚度(9.4±2.2mm)显著高于A组(7.8±1.4mm),P<0.05。周期排卵率C组(82.35%)>B组(76.92%)>A组(69.23%),但各组间无统计学差异(P>0.05);未破裂卵泡黄素化综合征(LUFS)发生率C组(5.88%)显著低于A组(23.08%)(P<0.05)。周期妊娠率C组(23.5%)>B组(15.4%)>A组(10.3%)(P<0.05)。结论:温肾活血汤能提高克罗米芬促排卵治疗后的妊娠率,其机制可能与促进排卵、降低LUFS发生及改善子宫内膜容受性有关,其改善内膜容受性的效果好于阿司匹林联合CC。     

自然周期冻融胚胎移植日雌二醇水平对妊娠结局的影响

目的探讨冻融胚胎移植时自然周期内膜准备中胚胎移植日雌二醇(E2)水平对妊娠结局的影响。方法选择2010年9月至2011年10月在沈阳市妇婴医院生殖中心进行冻融胚胎移植周期中,以自然周期进行内膜准备的患者110例,进行130个周期冻融胚胎移植。按移植日雌二醇水平分为4组:A组:E2≤183.5pmol/L14周期;B组:E2>183.5pmol/L,≤367.0pmol/L34周期;C组:E2>367.0pmol/L,≤734.0pmol/L74周期;D组:E2>734.0pmol/L8周期。对各组的年龄、子宫内膜厚度、移植胚胎数、临床妊娠率、胚胎种植率及流产率进行比较。结果各组年龄、子宫内膜厚度、移植胚胎数及流产率比较差异均无统计学意义。C组临床妊娠率和种植率分别为62.2%和30.9%,明显高于A组(42.9%,23.5%)和B组(52.9%,28.6%),P<0.05。B组临床妊娠率和种植率与A组比较有增高趋势,但差异无统计学意义,P>0.05。D组临床妊娠率为25.0%(2/8),胚胎种植率为10.0%(2/20)。D组因例数较少未进行统计学比较。结论在冻融胚胎移植周期中,以自然周期进行内膜准备时,胚胎移植日雌二醇水平过低或过高都影响临床妊娠率及胚胎种植率。     

hCG日子宫内膜厚度与体外受精-胚胎移植妊娠结局多中心回顾性研究

目的探讨h CG日子宫内膜厚度对体外受精-胚胎移植(IVF-ET)妊娠结局的影响。方法纳入2015-01-01—2015-12-31 8家生殖中心共3601个IVF-ET周期。在h CG注射日测量子宫内膜厚度,绘制子宫内膜厚度与助孕结局的分布表,根据子宫内膜厚度分为2组,A组(289个周期):h CG日子宫内膜厚度8mm,B组(3312个周期):h CG日子宫内膜厚度≥8mm。比较两组临床妊娠率、活产率、妊娠丢失率、单胎妊娠持续时间、单胎出生体重。结果 A、、47.0%(P=0.000),妊娠丢失率分别为23.3%、15.8%(P=0.024)。两组单胎分娩胎儿妊娠持续时间和单胎分娩胎儿体重比较差异无统计学意义。采用多因素logistic回归校正女方年龄、BMI、移植胚胎数后,B组与A组比较,临床妊娠率(a OR=1.492,P=0.001)与活产率(a OR=1.621,P=0.000)均增加。结论 h CG日子宫内膜厚度影响IVF-ET妊娠结局,子宫内膜厚度8mm时,IVF-ET的临床妊娠率与活产率较低,在患者进行移植策略决策时,应充分告知;但h CG日子宫内膜厚度不影响单胎妊娠的妊娠持续时间和胎儿出生体重。     

改良超长方案在卵巢储备功能低下高龄患者中的应用

目的:探讨改良超长方案行体外受精-胚胎移植(IVF-ET)助孕的高龄(年龄≥40岁)且卵巢储备功能低下(窦卵泡3~7个)患者的治疗结局。方法:采用随机对照前瞻研究的方法,将行IVF-ET的120例高龄且卵巢储备功能低下患者随机分成:改良超长方案组(A组,n=55)和拮抗剂方案组(B组,n=65),比较A、B组间IVF-ET结局。结果:A组的Gn使用总量(3 955.2±1194.3 IU)、Gn使用天数(11.7±1.9 d)、hCG注射日E2水平(2 452.7±1 285.6 pg/ml),hCG注射日子宫内膜厚度(12.1±2.3 mm)均明显高于B组(分别为2 022.5±610.1 IU、9.1±1.7 d、1 257.7±696.0 pg/ml、11.3±2.0 mm),P<0.05;周期取消率、优质胚胎率、妊娠率、着床率、流产率、宫外孕发生率组间均无统计学差异(P>0.05)。A组hCG注射日LH水平(1.0±0.5 mIU/ml)及P/E2值(0.3±0.2)明显低于B组(3.4±2.4 mIU/ml及0.5±0.2),P<0.05。结论:改良超长方案经过GnRHa的预处理,使患者充分降调节,hCG注射日可以获得良好的LH水平、P/E2值及内膜厚度;而hMG的使用,既可降低患者费用,又可以适当补充LH,提高子宫内膜容受性。因此,对于高龄且卵巢储备功能低下的患者,改良超长方案是一个经济有效的治疗选择。     

短方案降调节hCG注射日前后血清雌孕激素水平变化及其比值对IVF/ICSI结局的影响

目的:探讨体外受精-胚胎移植(IVF-ET)中hCG注射日前后血清雌孕激素水平变化及其比值对妊娠结局的影响。方法:选取行短方案治疗的137例不孕症患者的临床资料,根据hCG注射日每成熟卵泡(B超下直径≥14 mm的卵泡)的E2水平分为3组,A1组E2水平<450 pg/ml,A2组E2水平450~600 pg/ml,A3组E2水平>600 pg/ml;据hCG注射日较前一日E2增幅程度不同亦分为3组,B1组增幅程度<20%,B2组增幅程度20%~30%,B3组增幅程度>30%;另外为探讨hCG注射日雌、孕激素比值对妊娠结局的影响,按hCG注射日E2/P值不同亦分为3组,C1组E2/P<3,C2组E2/P=3~5,C3组E2/P>5;对上述3组的临床资料进行回顾性分析。结果:A2组的临床妊娠率高于A3组,A1和A2组的胚胎种植率亦高于A3组,差异均有统计学意义(P<0.05);B1组的临床妊娠率明显高于B2和B3组,B1组的胚胎种植率亦高于B3组,差异均有统计学意义(P<0.05);C3组的临床妊娠率高于C1组,差异有统计学意义(P<0.05);C2、C3组的胚胎种植率明显高于C1组,差异有统计学意义(P<0.05)。结论:行IVF-ET患者的hCG注射日前后适合水平的血清雌、孕激素及其比值(E2水平在450~600 pg/ml,hCG注射日前后E2增幅<20%及E2/P>5)能获得较好的妊娠结局。     

不同预处理促性腺激素拮抗剂方案在超促排卵中应用的临床分析

目的:探讨如何在体外受精-胚胎移植(IVF-ET)周期中更有效地运用拮抗剂方案。方法:回顾性分析319个使用拮抗剂方案进行IVF-ET无输卵管积液、无内膜息肉及无子宫解剖结构异常的新鲜移植周期。根据拮抗剂治疗前使用短效激动剂(n=125,A组)、口服避孕药(达英-35)(n=113,B组)和未处理组(n=81,C组)分组,比较各组患者的年龄、促性腺激素(Gn)使用天数和剂量、注射hCG日LH和E2水平、获卵数、优质胚胎率、临床妊娠率等。同时以261个促性腺激素激动剂长方案移植周期为对照组(D组)作进一步对比。结果:C组年龄(32.9±4.8岁)较其它组年龄明显偏大,P<0.05;A和B组Gn使用剂量大于C组,其中A组明显增多(P<0.01);A和B组hCG注射日LH水平均较C组明显低,其中A组LH值最低(P<0.01);A组获卵数最多(P<0.05);B组子宫内膜最薄(P<0.01)。3组的受精率、优质胚胎率均无统计学差异(P>0.05)。A组、B组和C组临床妊娠率分别为:32.8%、17.7%和37.0%,B组临床妊娠率显著低于A、C组(P<0.01)。C组、D组间临床妊娠率比较无统计学差异(37.0%vs 40.2%,P>0.05);C组Gn使用的时间和剂量均比D组明显减少(P<0.05)。结论:在IVF-ET中GnRH拮抗剂治疗前使用达必佳预处理未能提高妊娠率,使用过达因-35避孕的患者妊娠率明显下降,而未使用任何药物的患者接受GnRH拮抗剂超促排卵方案,能获得比较好的临床结局。     

hCG注射日雌二醇(E_2)增幅及每成熟卵泡E_2水平对控制性促排卵hCG扳机的影响

目的:探讨控制性促排卵(COS)hCG注射日雌二醇(E2)在hCG扳机时的作用。方法:接受长方案垂体降调节IVF/ICSI-ET助孕的不孕症患者1 811例,测量COS周期中E2水平,计算E2增幅[E2增幅=(hCG注射日E2值-hCG注射前日E2值)/hCG注射前日E2值]。按照E2的增幅分为5组:A1组E2增幅≤-10%,A2组E2增幅为-9%~10%,A3组E2增幅为11%~50%,A4组E2增幅为51%~100%,A5组E2增幅100%;另按hCG注射日每卵泡E2水平分为5组:B1组E2≤200 pg/ml,B2组E2为201~300 pg/ml,B3组E2为301~400 pg/ml,B4组E2为401~500 pg/ml,B5组E2500 pg/ml。比较各组间一般临床特征及IVF-ET的临床结局。结果:①A1组hCG注射日直径≥14 mm卵泡数、获卵数及2PN数较其他4组高,hCG注射日直径≥18 mm卵泡比例,较其他4组低,差异均有统计学意义(P0.05),临床妊娠率偏低,但与其余4组间无统计学差异(P0.05);②A5组hCG注射日P水平、hCG注射日直径≥14 mm卵泡数、获卵数、2PN数、临床妊娠率和胚胎着床率均较其他4组低,差异有统计学意义(P0.05);③B2组临床妊娠率和胚胎着床率较其他4组高,差异有统计学意义(P0.05)。结论:hCG注射日E2增幅介于-9%~100%、每成熟卵泡E2值介于201~300 pg/ml之间是hCG扳机的最佳时机。     

脱氢表雄酮(DHEA)预治疗在体外受精-胚胎移植周期中的应用

目的:探讨脱氢表雄酮(DHEA)预治疗在卵巢储备低下妇女的体外受精/卵胞质内单精子注射-胚胎移植(IVF/ICSI-ET)周期治疗中的作用。方法:对173例卵巢储备功能低下进行IVF/ICSI-ET的患者进行随机对照研究。DHEA预治疗组(n=81)患者口服DHEA,连用3个月,对照组为未服用DHEA预治疗者(n=92)。观察患者的一般情况、超促排卵情况及胚胎发育和妊娠结局。结果:患者一般情况、hCG注射日子宫内膜厚度及E2水平、Gn使用量和Gn使用天数组间均无统计学差异(P>0.05)。DHEA组IVF受精率、优质胚胎率及临床妊娠率均高于对照组(P<0.05)。但在胚胎种植率、早期流产率、周期取消率组间差异无统计学意义(P>0.05)。结论:DHEA预治疗可以改善卵巢储备功能低下妇女的IVF结局。     

Endometrial wave direction switch and the outcome of in vitro fertilization

OBJECTIVE: To describe endometrial wavelike activity, endometrial thickness and texture in IVF cycles, and to relate them to IVF outcome. To evaluate wave patterns on the day of hCG administration as a predictor of IVF outcome. DESIGN: Ultrasound study. SETTING: University hospital-based infertility clinic. PATIENT(S): Twenty-eight women undergoing IVF. INTERVENTION(S): Ultrasound examinations were performed at five fixed moments (start ovarian stimulation, hCG administration, ovum pickup (OPU), ET, and 7 days after hCG administration) and at three variable moments in the stimulation period in the cycle. The OPU was performed 2 days after hCG administration; ET was performed 2 or 3 days after that. MAIN OUTCOME MEASURE(S): Endometrial wave pattern, thickness, texture, IVF outcome. RESULT(S): Embryo transfer was performed in 22 cycles. In 73% of the cycles a wave direction switch (WDS) from fundus to cervix (FC) to cervix to fundus (CF) occurred before OPU. Eleven (50%) patients became pregnant. Significantly more FC waves persisted until hCG administration in the cycles in which the patients conceived. Endometrial thickness and texture were unrelated to IVF outcome. CONCLUSION(S): Endometrial wave pattern is associated with pregnancy in IVF. The persisting presence of FC waves until hCG administration (a late WDS) predicts a favorable IVF outcome.     

Increased endometrial thickness on the day of human chorionic gonadotropin injection does not adversely affect pregnancy or implantation rates following in vitro fertilization-embryo transfer

OBJECTIVES: To investigate the controversy whether an increased endometrial thickness has an effect on pregnancy, implantation, or abortion rates in in vitro fertilization-embryo transfer (IVF-ET) cycles. DESIGN: Retrospective analysis. SETTING: A university-based IVF center. PATIENT(S): Five hundred seventy women under the age of 40. INTERVENTION(S): Measurements of endometrial thickness on day of human chorionic gonadotropin (hCG) administration. Cycles were compared by endometrial thickness of 14 mm in 60 women. MAIN OUTCOME MEASURE(S): Implantation, pregnancy, and abortion rates. RESULT(S): Implantation, pregnancy, and abortion rates were similar in each group. In cycles where the endometrial thickness was 14 mm. CONCLUSION(S): No adverse effects of a thickened endometrium were demonstrated on implantation, pregnancy, or abortion rates in the first IVF-ET cycle. These findings fail to corroborate with those of Weissman et al. and support those of Yakin et al.     

Relationships between pregnancy rates following in vitro fertilization or intracytoplasmic sperm injection and endometrial thickness and pattern

OBJECTIVE: To investigate the role of endometrial thickness and pattern on the day of human chorionic gonadotropin (hCG) administration on in vitro fertilization (IVF)/intracytoplasmic injection (ICSI) outcome. STUDY DESIGN: A total of 150 infertile women undergoing embryo transfer after IVF/ICSI cycles were studied in a prospective survey. Sonographic features of the endometrium (thickness and pattern) on the day of hCG administration, hormonal profile (progesterone, estradiol, FSH, LH) and various other variables (maternal age, causes and duration of infertility, duration of treatment, number of human menopausal gonadotropin (hMG) ampoules administered, and number of oocytes retrieved) were evaluated. These variables in pregnant and nonpregnant patients were compared. RESULTS: There was no difference between pregnant and nonpregnant patients in mean endometrium thickness (10.1+/-1 versus 10.2+/-2, p=0.79). Pregnancies occurred only in patients with an endometrial thickness of 9-12 mm (p=0.036). Duration of treatment, number of hMG ampoules administered, number of oocytes retrieved, estradiol concentration, and estradiol/progesterone ratio on the day of hCG differed significantly between pregnant and nonpregnant patients. There was no correlation between endometrial pattern and pregnancy rate. The receiver-operating characteristic (ROC) curve and multiple logistic regression showed no significant effect of endometrial thickness in the outcome of IVF/ICSI. CONCLUSION: The sonographic features of the endometrium (thickness and pattern) on the day of hCG administration did not differ between pregnant and nonpregnant patients. The pregnancy rate declined beyond two limits of endometrial thickness.     

彩色多普勒超声监测子宫内膜和内膜下血流对IVF患者子宫容受性的预测价值

目的:评价彩色多普勒超声监测子宫内膜和内膜下血流在IVF-ET中对子宫内膜容受性的预测价值。方法:选择第一次进行IVF/ICSI-ET治疗的不孕症患者119例,根据注射hCG日子宫内膜和内膜下血流状况分为A组(n=8):子宫内膜和内膜下血流≤2支;B组(n=50):子宫内膜和内膜下血流3-4支;C组(n=61):子宫内膜和内膜下血流≥5支。各组患者均移植1-3个胚胎。比较各组的临床特征、卵巢反应、内膜情况和妊娠结局。结果:各组的临床特征、卵巢反应、内膜情况均无统计学差异,A组妊娠率低于B组(P<0.05)和C组(P<0.01)。A组着床率低于C组(P<0.01),B组和C组的妊娠率和着床率均无明显差异(P>0.05)。结论:子宫内膜和内膜下血流在IVF-ET中对子宫内膜容受性有一定预测价值。IVF-ET周期中内膜和内膜下血流≤2支者建议当月不做胚胎移植,可待血流改善后再行胚胎移植术。     

不同促排卵方案在卵巢低反应患者中的应用

目的:探讨不同促排卵方案在接受体外受精-胚胎移植(IVF-ET)的卵巢低反应患者中的应用价值。方法:对87例卵巢低反应患者采用不同方案进行IVF/ICSI-ET共200个周期的临床资料进行回顾性分析,其中短方案者50个周期(A组),拮抗剂方案者39个周期(B组),微刺激方案者93个周期(C组),自然周期方案者18个周期(D组)。比较分析各组的促排卵结局。结果:4组间周期取消率无统计学差异,hCG注射日LH水平A组低于其他3组,E2水平高于其他3组,与C、D组比有统计学差异(P<0.05),优势卵泡数及平均获卵数D组低于其他3组,而正常受精率高于其他3组,与A、B组比有统计学差异(P<0.05),hCG注射日内膜厚度、P值、MⅡ卵率、可利用胚胎率、临床妊娠率C组临床妊娠率略高,但各组间差异均无统计学意义(P>0.05)。结论:对卵巢低反应患者微刺激方案在IVF-ET促排卵中相对其他方案有更好的临床效果。     

Effects of ovarian high response on implantation and pregnancy outcome during controlled ovarian hyperstimulation (with GnRH agonist and rFSH)

BACKGROUND: The study was aimed at investigating the effects of ovarian high response during controlled ovarian hyperstimulation (COH) on implantation and pregnancy outcome in fresh IVF/ICSI cycles, and subsequent frozen-thawed embryo transfer (FET) cycles. METHODS: An analysis of 1,196 cycles using a long protocol with GnRHa and rFSH was performed. A serum oestrial level (peak E(2)) was obtained on the day of hCG administration, and patients were grouped by peak E(2) percentile distribution into 3 groups. Normal responder was set as cut-off concentrations between percentile (P)25 and P75 (Group A: 1,199-3,047 pg/ml, 595 cycles). Moderate high responders were classified as peak E(2) between P75-P90 (Group B: 3,048-4,127 pg/ml, 180 cycles). For the high response group, the E(2) cut-off concentration was set as P90 and above (Group C: >or=4,128 pg/ml, 119 cycles). Oocyte/embryo parameters and clinical outcomes were compared among the 3 groups in fresh cycles and subsequent FET cycles. RESULTS: Comparisons between groups revealed no difference in the quality of oocyte retrieved and in fertilisation rates. Group C showed decreased trends in implantation and pregnancy rates compared with Group A, but statistical significance was reached only for the difference in implantation rates. Implantation and pregnancy rates in FET cycles were similar among the 3 groups. CONCLUSIONS: High serum estrogen levels were detrimental to implantation, but not to the quality of oocytes, which may be due to an adverse effect on endometrial receptivity in COH cycles.     

The effect of endometrial thickness on the day of hCG administration on pregnancy outcome in the first fresh IVF/ICSI cycle

The aim of this study was to investigate the effect of endometrial thickness (EMT) on human chorionic gonadotropin (hCG) day on in vitro fertilization/intracytoplasmic sperm injection (IVF/ICSI) outcome. A retrospective study was conducted on the clinical data of 756 patients in their first fresh IVF/ICSI cycle at the Wuxi Maternity and Child Health Hospital. Compared with the pregnancy failure group, the clinical pregnancy group had more transferable embryos and good-quality embryos and had a thicker endometrium (p?<?0.05). The endometrial pattern was not significantly different between the two groups. EMT was found to be an independent prognostic factor for clinical pregnancy (adjusted OR?=?1.25, 95% CI: 1.15–1.36, p?<?0.01). Seven hundred and fifty-six cycles were categorized into three groups upon EMT on the hCG day: group 1 (EMT??14?mm). Group1 had significantly lower clinical pregnancy, embryo implantation and live birth rates compared with group 2 and 3 (p?<?0.01), while there was no significant difference in either spontaneous abortion or multiple-birth rate among these three groups. It was concluded that EMT on the hCG day was associated with pregnancy outcome in the first fresh IVF/ICSI cycle. A higher clinical pregnancy rate could be achieved when EMT?≥?8?mm, and no adverse pregnancy outcome was observed when EMT?>?14?mm.